Search Bar & Filters
Found 78 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a blended e-health intervention designed to improve fear of progression FOP in women with advanced or certain types of gynecologic or breast cancer. Fear of progression refers to the worry patients experience about their cancer growing or worsening, which is linked to distress, depression, and higher health care costs. This trial aims to determine whether the intervention is feasible, acceptable, and effective in reducing FOP and related psychological symptoms. Participants are randomly assigned to one of two groups over six weeks. One group takes part in the Mindful Living Program, which includes weekly group sessions and online sessions focusing on mindfulness and coping skills, daily practice of mindfulness techniques, check-in phone calls, and access to supportive online resources. The other group participates in the Navigating Cancer Program with similar group and online sessions and a check-in call but without the additional mindfulness practices or web resources. After the intervention, participants are followed up at 12 weeks. During the study, participants complete surveys measuring fear of progression, distress, anxiety, metacognitions, and mindfulness at the start, at six weeks, and again at 12 weeks. Researchers also monitor attendance, engagement, usability of the intervention, and recruitment and retention rates. The study includes remote group sessions, check-in calls, and access to online videos, a journal, and a community forum. Participation lasts approximately 12 weeks from baseline to follow-up.
Actively Recruiting
Researchers are evaluating tulisokibart as a treatment for radiographic axial spondyloarthritis r-axSpA, a type of arthritis causing pain, stiffness, and inflammation in the spine and pelvis joints. This condition leads to damage visible on X-rays. The study aims to find out if different doses of tulisokibart improve symptoms better than a placebo, which looks like the medicine but contains no active drug. Participants will be assigned to one of four groups a high dose, medium dose, low dose of tulisokibart, or a placebo. After 16 weeks, those on the low dose or placebo will be randomly reassigned to receive either the medium or high dose. The study includes a 16-week placebo-controlled period followed by a 124-week long-term extension, which consists of a 40-week main extension and an 84-week optional extension. Tulisokibart is given through subcutaneous injections. During the study, participants will undergo assessments of their arthritis symptoms using various scales and imaging, including MRI scans of the spine and pelvis. Researchers will monitor changes in pain, function, disease activity, and fatigue at baseline and after 16 weeks. Safety will be tracked throughout the study and for up to about 154 weeks. The study is scheduled to complete in early 2030.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how cannabis use affects the quality of life in patients with multiple myeloma who are receiving chemotherapy. This observational study compares patients who use cannabis with those who do not, aiming to understand both potential benefits and harms. It uses specific tools like the Functional Assessment of Cancer Therapy-Multiple Myeloma FACT-MM and patient-reported symptoms to assess these effects over time. Participants are divided into two groups one group completes surveys and provides blood samples throughout the study, and the other group consists of healthcare providers who complete a survey related to the study. The study follows participants for up to one year, focusing on longitudinal patterns in quality of life and the potential therapeutic benefits and adverse effects associated with cannabis use. During the study, patients complete questionnaires and provide blood samples regularly. Researchers monitor their symptoms and any side effects using standardized scales such as the Edmonton Symptoms Assessment Scale and Common Terminology Criteria for Adverse Events. The study tracks changes over time to better understand how cannabis use interacts with cancer-directed treatments and overall patient well-being.
Actively Recruiting
Researchers are investigating the effects of APL-3007 combined with SyfovrePegcetacoplan APL-2 in patients with geographic atrophy caused by age-related macular degeneration AMD. This Phase 2 randomized, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacodynamics of these treatments in this eye condition. The study involves multiple centers and uses a masked design to ensure unbiased results. Participants will be assigned to one of three groups two receiving different doses or frequencies of APL-3007 in combination with pegcetacoplan APL-2, and one receiving a placebo along with pegcetacoplan APL-2. The study will evaluate the treatments given as multidose regimens. The treatments focus on complement C3 inhibition to potentially impact disease progression. Throughout the study, participants will undergo assessments including artificial intelligence-based imaging to measure retinal pigment epithelium lesion area and photoreceptor degeneration, safety evaluations through adverse event reporting and visual acuity tests, and blood tests to assess serum markers. These evaluations occur over 12 months to monitor changes from baseline. Participants involvement includes regular visits for these assessments, with the study tracking treatment effects and safety over the duration.
Actively Recruiting
Researchers are evaluating the effects of camoteskimab in adults aged 18 to 65 with moderate-to-severe atopic dermatitis. This phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of camoteskimab compared to placebo. Participants include those who are treatment-naive or have had an inadequate response to previous biologic therapies. The study has two parts Part 1 is a 24-week placebo-controlled period where participants are randomly assigned to one of three camoteskimab dose levels or placebo, all administered by subcutaneous injection. In Part 2, an extension period, all participants receive camoteskimab. This design allows comparison of different dose levels and monitoring of long-term treatment effects. Participants will be assessed regularly throughout the study with measures including the Eczema Area and Severity Index EASI, Investigator Global Assessment IGA, and peak pruritus numerical rating scale PP-NRS. Safety and efficacy will be monitored through these assessments over 24 weeks and beyond. The study includes signing informed consent and adherence tracking, with the primary outcome focused on percentage change in EASI score from baseline to Week 24.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a subretinal implant called CPCB-RPE1 in people with advanced dry age-related macular degeneration AMD that includes geographic atrophy involving the fovea. This Phase IIb randomized clinical trial compares the implant to a simulated sham procedure to understand its impact on retinal sensitivity and vision. Participants will be randomly assigned to one of two groups up to 18 participants will receive the CPCB-RPE1 implant through surgery, while up to 6 participants will undergo a sham implantation procedure. The study involves up to 6 surgical implantation sites, with additional sites serving as referral or follow-up locations. During the trial, participants will undergo assessments including retinal sensitivity testing and best-corrected visual acuity measurements, with primary outcomes evaluated one year after implantation. The study includes careful monitoring of vision changes and safety over time, lasting until December 2040, to gather comprehensive data on the implants performance.
Actively Recruiting
Researchers are evaluating the effect on LDL cholesterol LDL-C and the safety and tolerability of a fixed-dose combination FDC of Laroprovstat and Rosuvastatin in patients who have not previously received lipid-lowering treatment LLT. Laroprovstat is a small molecule developed to reduce LDL-C in the blood, and this Phase III randomized study compares this combination with Laroprovstat alone, Rosuvastatin alone, and placebo in people with hypercholesterolaemia. Participants will be randomly assigned to one of several groups receiving daily oral doses of Laroprovstat, Rosuvastatin at two dose levels, the combination LaroprovstatRosuvastatin at two dose levels, or placebo matching these treatments. The study uses a factorial design and is double-blind, meaning neither participants nor researchers know which treatment is given. Treatment lasts for 8 weeks with assessments focused on changes in LDL-C levels. During the study, participants will attend visits for evaluations including blood tests to measure LDL-C and other cholesterol-related markers such as Apo B, non-HDL cholesterol, and total cholesterol. The main outcome measured is the relative change in LDL-C at 8 weeks. Safety and tolerability will also be monitored throughout. The entire participation period covers the treatment and assessment over the 8-week period.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating the safety, pharmacokinetics, and activity of the drug divarasib alone or combined with other anti-cancer treatments in adults with previously untreated advanced or metastatic non-small cell lung cancer NSCLC that has a KRAS G12C mutation. This phase IbII open-label study involves participants who have not received prior systemic treatment for advanced or metastatic NSCLC and aims to better understand how divarasib works and its side effects. Participants will be assigned to different groups receiving divarasib orally once daily at varying dose levels combined with pembrolizumab given as an intravenous infusion every three weeks. Some groups will also receive platinum-based chemotherapy carboplatin or cisplatin and pemetrexed. The study includes dose finding and dose expansion stages, with some participants randomized to different combination dose levels of divarasib and pembrolizumab. During the study, participants will be monitored for adverse events from baseline until 60 days after the last dose or until starting another anti-cancer therapy, up to about five years. Researchers will assess response rates, duration of response, progression-free survival, symptom side effects through patient questionnaires, and drug levels in plasma or cerebrospinal fluid. Safety and activity will be observed through regular clinical visits, imaging, and laboratory tests throughout the study period.
Actively Recruiting
Researchers are evaluating how well different doses of the medicine BI 3812465 are tolerated in adults with diabetic macular edema that affects the center of the eye. This is the first time BI 3812465 is given to humans. The study includes two parts an initial phase testing low, medium, and high doses sequentially, followed by a phase where more participants receive these doses in a randomized way to assess safety and tolerability. Participants receive BI 3812465 as injections into the back of the eye, with a total of three injections given during the study. In Part 1, a small group receives increasing doses starting from low, and in Part 2, a larger group is randomized to receive one of the three dose levels. The treatment period involves these injections, and dosing only advances if lower doses are tolerated. Participants stay in the study for up to 7 months, attending 19 visits to the study site or, when possible, having visits at their home. During these visits, doctors check the severity of the eye condition and monitor for any health problems related to the medicine. The study measures dose limiting events, ocular adverse events, and other safety outcomes throughout the treatment and follow-up period.
1-10 of 78
1